Articles producció científica> Ciències Mèdiques Bàsiques

Immunotherapy and Hypofractionated Radiotherapy in Older Patients with Locally Advanced Cutaneous Squamous-Cell Carcinoma of the Head and Neck: A Proposed Paradigm by the International Geriatric Radiotherapy Group

  • Dades identificatives

    Identificador: imarina:9331524
    Autors:
    Nguyen, NPThariat, JGorobets, OVinh-Hung, VKim, LBlanco, SCVasileiou, MArenas, MMazibuko, TGiap, HVincent, FChi, ALoganadane, GMohammadianpanah, MRembielak, AKarlsson, UAli, ABose, SPage, BR
    Resum:
    Cutaneous skin carcinoma is a disease of older patients. The prevalence of cutaneous squamous-cell carcinoma (cSCC) increases with age. The head and neck region is a frequent place of occurrence due to exposure to ultraviolet light. Surgical resection with adjuvant radiotherapy is frequently advocated for locally advanced disease to decrease the risk of loco-regional recurrence. However, older cancer patients may not be candidates for surgery due to frailty and/or increased risk of complications. Radiotherapy is usually advocated for unresectable patients. Compared to basal-cell carcinoma, locally advanced cSCC tends to recur locally and/or can metastasize, especially in patients with high-risk features such as poorly differentiated histology and perineural invasion. Thus, a new algorithm needs to be developed for older patients with locally advanced head and neck cutaneous squamous-cell carcinoma to improve their survival and conserve their quality of life. Recently, immunotherapy with checkpoint inhibitors (CPIs) has attracted much attention due to the high prevalence of program death ligand 1 (PD-L1) in cSCC. A high response rate was observed following CPI administration with acceptable toxicity. Those with residual disease may be treated with hypofractionated radiotherapy to minimize the risk of recurrence, as radiotherapy may enhance the effect of immunotherapy. We propose a protocol combining CPIs and hypofractionated radiotherapy for older patients with locally advanced cutaneous head and neck cancer who are not candidates for surgery. Prospective studies should be performed to verify this hypothesis.
  • Altres:

    Autor segons l'article: Nguyen, NP; Thariat, J; Gorobets, O; Vinh-Hung, V; Kim, L; Blanco, SC; Vasileiou, M; Arenas, M; Mazibuko, T; Giap, H; Vincent, F; Chi, A; Loganadane, G; Mohammadianpanah, M; Rembielak, A; Karlsson, U; Ali, A; Bose, S; Page, BR
    Departament: Ciències Mèdiques Bàsiques
    Autor/s de la URV: Arenas Prat, Meritxell
    Paraules clau: Radiation-therapy Older Locally advanced Hypofractionated radiotherapy Cutaneous squamous cell Cpis tumor survival skin-cancer pembrolizumab pd-l1 expression locally advanced hypofractionated radiotherapy gender disparities cutaneous squamous cell cpis clinical-trials basal-cell
    Resum: Cutaneous skin carcinoma is a disease of older patients. The prevalence of cutaneous squamous-cell carcinoma (cSCC) increases with age. The head and neck region is a frequent place of occurrence due to exposure to ultraviolet light. Surgical resection with adjuvant radiotherapy is frequently advocated for locally advanced disease to decrease the risk of loco-regional recurrence. However, older cancer patients may not be candidates for surgery due to frailty and/or increased risk of complications. Radiotherapy is usually advocated for unresectable patients. Compared to basal-cell carcinoma, locally advanced cSCC tends to recur locally and/or can metastasize, especially in patients with high-risk features such as poorly differentiated histology and perineural invasion. Thus, a new algorithm needs to be developed for older patients with locally advanced head and neck cutaneous squamous-cell carcinoma to improve their survival and conserve their quality of life. Recently, immunotherapy with checkpoint inhibitors (CPIs) has attracted much attention due to the high prevalence of program death ligand 1 (PD-L1) in cSCC. A high response rate was observed following CPI administration with acceptable toxicity. Those with residual disease may be treated with hypofractionated radiotherapy to minimize the risk of recurrence, as radiotherapy may enhance the effect of immunotherapy. We propose a protocol combining CPIs and hypofractionated radiotherapy for older patients with locally advanced cutaneous head and neck cancer who are not candidates for surgery. Prospective studies should be performed to verify this hypothesis.
    Àrees temàtiques: Oncology Medicina iii Cancer research
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: meritxell.arenas@urv.cat
    Identificador de l'autor: 0000-0003-0815-2570
    Data d'alta del registre: 2024-08-03
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.mdpi.com/2072-6694/15/20/4981
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Cancers. 15 (20):
    Referència de l'ítem segons les normes APA: Nguyen, NP; Thariat, J; Gorobets, O; Vinh-Hung, V; Kim, L; Blanco, SC; Vasileiou, M; Arenas, M; Mazibuko, T; Giap, H; Vincent, F; Chi, A; Loganadane, (2023). Immunotherapy and Hypofractionated Radiotherapy in Older Patients with Locally Advanced Cutaneous Squamous-Cell Carcinoma of the Head and Neck: A Proposed Paradigm by the International Geriatric Radiotherapy Group. Cancers, 15(20), -. DOI: 10.3390/cancers15204981
    DOI de l'article: 10.3390/cancers15204981
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2023
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cancer Research,Oncology
    Radiation-therapy
    Older
    Locally advanced
    Hypofractionated radiotherapy
    Cutaneous squamous cell
    Cpis
    tumor
    survival
    skin-cancer
    pembrolizumab
    pd-l1 expression
    locally advanced
    hypofractionated radiotherapy
    gender
    disparities
    cutaneous squamous cell
    cpis
    clinical-trials
    basal-cell
    Oncology
    Medicina iii
    Cancer research
  • Documents:

  • Cerca a google

    Search to google scholar